Blueprint Medicines Corp 2025年季度报告

FORM10-Q (Mark One) ☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period endedMarch31,2025 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 Commission file number001-37359_____________________________ BLUEPRINT MEDICINES CORPORATION (Exact Name of Registrant as Specified in Its Charter)_____________________________ 26-3632015(I.R.S.EmployerIdentificationNo.) Delaware(State or Other Jurisdiction ofIncorporation or Organization) 45 Sidney StreetCambridge,Massachusetts(Address of Principal Executive Offices) Indicate by check mark whether the registrant: (1)has filed all reports required to be filed by Section13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and(2)has been subject to such filing requirements for the past 90 days.Yes☑No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).Yes☑No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☑ TABLEOFCONTENTS PART I – FINANCIAL INFORMATION Item 1. Financial Statements (unaudited)4Condensed Consolidated Balance Sheets as of March 31, 2025 and December 31,20244Condensed Consolidated Statements of Operations and Comprehensive Income forthe three months ended March 31, 2025 and 20245Condensed Consolidated Statements of Stockholders’ Equity for the three monthsended March 31, 2025 and 20246Condensed Consolidated Statements of Cash Flows for the three months ended March31, 2025 and 20247Notes to Condensed Consolidated Financial Statements8Item 2. Management’s Discussion and Analysis of Financial Condition and Results ofOperations33Item 3. Quantitative and Qualitative Disclosures About Market Risk50Item 4. Controls and Procedures51 PART II – OTHER INFORMATION Item 1. Legal ProceedingsItem 1A. Risk FactorsItem 5. Other Information 5252105 Signatures107 Unless otherwise stated, all references to “us,” “our,” “Blueprint,” “Blueprint Medicines,”“we,” the “Company” and similar designations in this Quarterly Report on Form 10-Q refer toBlueprint Medicines Corporation and its consolidated subsidiaries. Blueprint Medicines, AYVAKIT®,AYVAKYT®, and associated logos are trademarks of Blueprint Medicines Corporation. GAVRETO®and associated logos are trademarks of Blueprint Medicines Corporation outside of the UnitedStates.Other brands, names and trademarks contained in this Quarterly Report on Form 10-Q arethe property of their respective owners. FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements that involvesubstantial risks and uncertainties. All statements, other than statements of historical facts, containedin this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you canidentify forward-looking statements by words such as “aim,” “anticipate,” “believe,” “contemplate,”“continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “opportunity,”“predict,” “project,” “seek,” “should,” “target,” “will,” “would” or a variation or the negative of thesewords or other comparable terminology, although not all forward-looking statements contain theseidentifying words. The forward-looking statements in this Quarterly Report on Form 10-Q include, but are notlimited to, statements about: ●the timing or likelihood of regulatory actions, filings and approvals for our currentand future drug candidates, including our ability to obtain marketing approval foravapritinib in additional geographies;●our ability and plans in continuing to build out our commercial infrastructure andsuccessfully launching, marketing and selling AYVAKIT®(avapritinib) (marketedin Europe under the brand name AYVAKYT®) and any current and future drugcandidates for which we receive marketing approval;●our expectations regarding the potential benefits of AYVAKIT/AYVAKYT and anycurrent and future drug candidates in treating patients with indolent systemicmastocytosis (SM) and advanced SM;●the